Psychiatry and Neurology, Neurology · Amherst, NY
NPI
1477998060
Since 2013
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
3980a Sheridan Dr Fl 2
Amherst, NY, 14226
Phone (716) 250-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$229K
7,176 services
Medicare patients, 2024
104
Average age 64
Drug cost, 2024
$3.9M
2,025 prescriptions
Company payments, 2025
$73K
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Svetlana P Eckert was code 99215 (office e&m - established), 67 times for 49 patients. In total Svetlana P Eckert billed 7,176 services in 27 codes, and Medicare paid $229K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 67 | 49 | $115.62 | $7,747 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 39 | 29 | $11.71 | $457 |
| 96365 Intravenous Infusion, Hydration | Office | 32 | 14 | $45.48 | $1,455 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 23 | 16 | $20.73 | $477 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 17 | 11 | $0.65 | $11 |
| 96413 Chemotherapy Administration | Office | 14 | 14 | $91.08 | $1,275 |
By year: 2022 $347K for 9,642 services; 2023 $395K for 9,609 services; 2024 $229K for 7,176 services.
Medicare prescription drug claims, 2024
In 2024, the drug Svetlana P Eckert prescribed most often to Medicare patients was Baclofen, with 171 prescriptions and refills. In total Svetlana P Eckert wrote 2,025 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Baclofen Generic | 171 | 269 | 38 | $3,387 |
| Gabapentin Generic | 170 | 293 | 40 | $5,211 |
| Dalfampridine Er Dalfampridine | 125 | 135 | 23 | $44K |
| Tizanidine Hcl Generic | 96 | 156 | 22 | $1,201 |
| Famotidine Generic | 70 | 94 | 18 | $348 |
| Teriflunomide Generic | 69 | 81 | Under 11 | $230K |
| Kesimpta Pen Ofatumumab | 61 | 61 | Under 11 | $551K |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 59 | 59 | Under 11 | $380K |
| Copaxone Glatiramer Acetate | 48 | 55 | Under 11 | $307K |
| Duloxetine Hcl Generic | 48 | 92 | Under 11 | $1,232 |
| Prednisone Generic | 44 | 44 | 13 | $159 |
| Pregabalin Generic | 36 | 50 | Under 11 | $1,158 |
| Lacosamide Generic | 36 | 38 | Under 11 | $6,828 |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | 36 | 36 | Under 11 | $307K |
| Methylprednisolone Sodium Succ Methylprednisolone Sod Succ | 35 | 35 | Under 11 | $1,040 |
Brand drugs: 406 claims; generic drugs: 1,619 claims; opioid claims: 19.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Svetlana P Eckert $73K ($73K in general payments such as food, travel and fees) from 13 companies. The largest payer was EMD Serono, Inc. with $40K.
| Company | Payments | Amount |
|---|---|---|
| EMD Serono, Inc. MRK.DE | 31 | $40K |
| TG Therapeutics, Inc. TGTX | 24 | $24K |
| Merck Sharp & Dohme LLC MRK | 10 | $7,142 |
| Amgen Inc. AMGN | 17 | $275 |
| Genentech USA, Inc. ROG.SW | 9 | $217 |
| Pfizer Inc. PFE | 13 | $214 |
| Alexion Pharmaceuticals, Inc. AZN | 2 | $52.09 |
| Celgene Corporation BMY | 2 | $35.43 |
| Eisai Inc. 4523.T | 1 | $33.07 |
| Abbvie Inc. ABBV | 1 | $29.86 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.